Eton Pharmaceuticals Inc. (ETON)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals Q2 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals (ETON) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Eton Pharmaceuticals (ETON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
Eton Pharmaceuticals (ETON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
The mean of analysts' price targets for Eton Pharmaceuticals (ETON) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
